Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (887) 887
Publication (112) 112
Book Review (15) 15
Book Chapter (12) 12
Conference Proceeding (7) 7
Book / eBook (3) 3
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (783) 783
index medicus (521) 521
uveal melanoma (482) 482
melanoma (434) 434
oncology (372) 372
female (365) 365
male (344) 344
melanoma - pathology (305) 305
uveal neoplasms - pathology (304) 304
melanoma - drug therapy (303) 303
middle aged (285) 285
aged (261) 261
cancer (254) 254
uveal neoplasms - drug therapy (251) 251
ophthalmology (248) 248
adult (245) 245
metastasis (235) 235
melanoma - genetics (193) 193
animals (173) 173
tumors (143) 143
cell line, tumor (142) 142
ocular melanoma (134) 134
prognosis (134) 134
melanoma - secondary (132) 132
uveal neoplasms - genetics (131) 131
care and treatment (129) 129
aged, 80 and over (128) 128
choroidal melanoma (128) 128
melanoma - metabolism (124) 124
treatment outcome (123) 123
liver neoplasms - secondary (122) 122
survival (121) 121
chemotherapy (115) 115
expression (115) 115
malignant-melanoma (110) 110
mutation (109) 109
antineoplastic agents - therapeutic use (102) 102
melanoma - therapy (97) 97
uveal neoplasms - metabolism (96) 96
mice (90) 90
analysis (81) 81
apoptosis (79) 79
therapy (76) 76
mutations (75) 75
skin neoplasms - pathology (75) 75
metastases (73) 73
research (73) 73
article (72) 72
dermatology (72) 72
retrospective studies (70) 70
uveal neoplasms - therapy (69) 69
liver neoplasms - drug therapy (68) 68
neoplasm metastasis (68) 68
gene expression (66) 66
melanoma - mortality (66) 66
skin neoplasms - drug therapy (66) 66
melanoma - radiotherapy (63) 63
antineoplastic combined chemotherapy protocols - therapeutic use (62) 62
proteins (61) 61
liver (60) 60
survival rate (60) 60
antineoplastic agents - pharmacology (59) 59
patients (59) 59
cutaneous melanoma (58) 58
health aspects (58) 58
liver metastases (58) 58
skin neoplasms - genetics (58) 58
medicine, research & experimental (57) 57
cell biology (56) 56
radiotherapy (56) 56
genetic aspects (55) 55
medicine & public health (55) 55
drug therapy (54) 54
follow-up studies (54) 54
medical prognosis (53) 53
metastatic melanoma (53) 53
cell proliferation - drug effects (51) 51
development and progression (51) 51
immunotherapy (51) 51
pathology (50) 50
uveal neoplasms - mortality (50) 50
angiogenesis (49) 49
cells (49) 49
eye diseases (49) 49
surgery (49) 49
tumor cells, cultured (49) 49
cancer therapies (48) 48
immunohistochemistry (48) 48
uveal neoplasms - radiotherapy (48) 48
medicine (47) 47
eye (45) 45
kinases (45) 45
survival analysis (44) 44
melanoma - diagnosis (43) 43
risk factors (43) 43
activation (42) 42
cancer research (42) 42
cell proliferation (42) 42
growth (42) 42
neoplasm staging (42) 42
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (874) 874
French (7) 7
German (5) 5
Japanese (2) 2
Portuguese (2) 2
Russian (2) 2
Hebrew (1) 1
Hungarian (1) 1
Italian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
by Falchook, Gerald S, Dr and Lewis, Karl D, MD and Infante, Jeffrey R, MD and Gordon, Michael S, MD and Vogelzang, Nicholas J, MD and DeMarini, Douglas J, PhD and Sun, Peng, PhD and Moy, Christopher, MS and Szabo, Stephen A, BA and Roadcap, Lori T, MS and Peddareddigari, Vijay GR, MD and Lebowitz, Peter F, MD and Le, Ngocdiep T, MD and Burris, Howard A, MD and Messersmith, Wells A, MD and O'Dwyer, Peter J, Prof and Kim, Kevin B, MD and Flaherty, Keith, MD and Bendell, Johanna C, MD and Gonzalez, Rene, Prof and Kurzrock, Razelle, Prof and Fecher, Leslie A, MD
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 782 - 789
Summary Background MEK is a member of the MAPK signalling cascade that is commonly activated in melanoma. Direct inhibition of MEK blocks cell proliferation... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | BRAF | ONCOLOGY | RAF | SOMATIC MUTATIONS | PROGRESSION | Skin Neoplasms - drug therapy | United States | Humans | Middle Aged | Melanoma - enzymology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Uveal Neoplasms - enzymology | Young Adult | Pyridones - administration & dosage | Skin Neoplasms - enzymology | Time Factors | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | MAP Kinase Kinase 1 - antagonists & inhibitors | Uveal Neoplasms - genetics | Uveal Neoplasms - pathology | Drug Administration Schedule | Administration, Oral | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | MAP Kinase Kinase 1 - metabolism | Treatment Outcome | MAP Kinase Kinase 2 - metabolism | Melanoma - pathology | Uveal Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | MAP Kinase Kinase 2 - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Uveal Neoplasms - mortality | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Prevention | Care and treatment | Melanoma | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma
by Shoushtari, Alexander N and Munhoz, Rodrigo R and Kuk, Deborah and Ott, Patrick A and Johnson, Douglas B and Tsai, Katy K and Rapisuwon, Suthee and Eroglu, Zeynep and Sullivan, Ryan J and Luke, Jason J and Gangadhar, Tara C and Salama, April K. S and Clark, Varina and Burias, Clare and Puzanov, Igor and Atkins, Michael B and Algazi, Alain P and Ribas, Antoni and Wolchok, Jedd D and Postow, Michael A
Cancer, ISSN 0008-543X, 11/2016, Volume 122, Issue 21, pp. 3354 - 3362
BACKGROUND Therapeutic antibodies against programmed cell death receptor 1 (PD‐1) are considered front‐line therapy in metastatic melanoma. The efficacy of... 
pembrolizumab | mucosal melanoma | anti‐programmed cell death receptor 1 (anti‐PD‐1) | acral melanoma | nivolumab | immunotherapy | anti-programmed cell death receptor 1 (anti-PD-1) | CTLA-4 BLOCKADE | SAFETY | PD-1 BLOCKADE | BIOCHEMOTHERAPY | CANCER | UNTREATED MELANOMA | UVEAL MELANOMA | ONCOLOGY | IPILIMUMAB | Prognosis | Skin Neoplasms - drug therapy | Follow-Up Studies | Humans | Middle Aged | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Brain Neoplasms - secondary | Antibodies, Monoclonal, Humanized - administration & dosage | Brain Neoplasms - immunology | Aged, 80 and over | Adult | Female | Retrospective Studies | Mucous Membrane - drug effects | Liver Neoplasms - secondary | Skin Neoplasms - pathology | Skin Neoplasms - immunology | Liver Neoplasms - drug therapy | Liver Neoplasms - immunology | Survival Rate | Melanoma - pathology | Brain Neoplasms - drug therapy | Mucous Membrane - pathology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - immunology | Melanoma - drug therapy | Aged | Programmed Cell Death 1 Receptor - immunology | Neoplasm Staging | Care and treatment | Research | Diagnosis | Melanoma | Apoptosis | Index Medicus | Abridged Index Medicus | anti-PD-1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience
by Luke, Jason J and Callahan, Margaret K and Postow, Michael A and Romano, Emanuela and Ramaiya, Nikhil and Bluth, Mark and Giobbie-Hurder, Anita and Lawrence, Donald P and Ibrahim, Nageatte and Ott, Patrick A and Flaherty, Keith T and Sullivan, Ryan J and Harding, James J and D'Angelo, Sandra and Dickson, Mark and Schwartz, Gary K and Chapman, Paul B and Wolchok, Jedd D and Hodi, F. Stephen and Carvajal, Richard D
Cancer, ISSN 0008-543X, 10/2013, Volume 119, Issue 20, pp. 3687 - 3695
Uveal melanoma exhibits a high incidence of metastases; and, to date, there is no systemic therapy that clearly improves outcomes. The anticytotoxic... 
absolute lymphocyte count | cytotoxic T-lymphocyte - associated protein 4 | uveal melanoma | immunotherapy | ipilimumab | Prognosis | Skin Neoplasms - drug therapy | Follow-Up Studies | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Universities | Neoplasm Metastasis | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Retrospective Studies | Uveal Neoplasms - pathology | Survival Rate | Melanoma - pathology | CTLA-4 Antigen - immunology | Uveal Neoplasms - drug therapy | Melanoma - drug therapy | Skin Neoplasms - secondary | Uveal Neoplasms - mortality | Aged | CTLA-4 Antigen - antagonists & inhibitors | Neoplasm Staging | Melanoma - mortality | Eye cancer | Patient outcomes | Melanoma | Dosage and administration | Research | Drug therapy | Index Medicus | Abridged Index Medicus | CTLA-4
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
by Maio, M and Danielli, R and Chiarion-Sileni, V and Pigozzo, J and Parmiani, G and Ridolfi, R and De Rosa, F and Del Vecchio, M and Di Guardo, L and Queirolo, P and Picasso, V and Marchetti, P and De Galitiis, F and Mandalà, M and Guida, M and Simeone, E and Ascierto, P.A
Annals of Oncology, ISSN 0923-7534, 11/2013, Volume 24, Issue 11, pp. 2911 - 2915
Patients with advanced uveal melanoma have a poor prognosis and limited treatment options. Ipilimumab is approved for pre-treated adult patients with advanced... 
Expanded access programme | Uveal melanoma | Efficacy | Metastatic melanoma | Safety | Ipilimumab | MANAGEMENT | ONCOLOGY | metastatic melanoma | uveal melanoma | safety | ipilimumab | BRAF | ABSENCE | MUTATIONS | efficacy | expanded access programme | PROGRESSION | Skin Neoplasms - pathology | Skin Neoplasms - drug therapy | Uveal Neoplasms - pathology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Treatment Outcome | Melanoma - pathology | Uveal Neoplasms - drug therapy | Disease-Free Survival | Neoplasm Metastasis | Antibodies, Monoclonal - administration & dosage | Skin Neoplasms - mortality | Melanoma - drug therapy | Uveal Neoplasms - mortality | Aged, 80 and over | Adult | Female | Aged | Neoplasm Staging | Melanoma - mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies
by Algazi, Alain P and Tsai, Katy K and Shoushtari, Alexander N and Munhoz, Rodrigo R and Eroglu, Zeynep and Piulats, Josep M and Ott, Patrick A and Johnson, Douglas B and Hwang, Jimmy and Daud, Adil I and Sosman, Jeffrey A and Carvajal, Richard D and Chmielowski, Bartosz and Postow, Michael A and Weber, Jeffrey S and Sullivan, Ryan J
Cancer, ISSN 0008-543X, 11/2016, Volume 122, Issue 21, pp. 3344 - 3353
BACKGROUND Antibodies inhibiting the programmed death receptor 1 (PD‐1) have demonstrated significant activity in the treatment of advanced cutaneous melanoma.... 
pembrolizumab | atezolizumab | nivolumab | uveal melanoma | immunotherapy | SURVIVAL | CTLA-4 BLOCKADE | SAFETY | CHEMOTHERAPY | RESPONSES | ONCOLOGY | MUTATIONS | ANTI-PD-1 | IPILIMUMAB | Prognosis | Follow-Up Studies | Humans | Middle Aged | Male | Antibodies, Monoclonal, Humanized - administration & dosage | Aged, 80 and over | Adult | Female | Retrospective Studies | Mucous Membrane - drug effects | Uveal Neoplasms - pathology | Survival Rate | Melanoma - pathology | B7-H1 Antigen - immunology | Uveal Neoplasms - drug therapy | Mucous Membrane - pathology | Uveal Neoplasms - immunology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - immunology | Melanoma - drug therapy | Skin Neoplasms | Aged | Programmed Cell Death 1 Receptor - immunology | Neoplasm Staging | Viral antibodies | Care and treatment | Usage | Melanoma | Antibodies | Research | Patients | Health aspects | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Reirradiation of Recurrent and Second Primary Head and Neck Cancer with Proton Therapy
by McDonald, Mark W., MD and Zolali-Meybodi, Omid, BS and Lehnert, Stephen J., BSc and Estabrook, Neil C., MD and Liu, Yuan, PhD, MS and Cohen-Gadol, Aaron A., MD, MSc and Moore, Michael G., MD
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2016, Volume 96, Issue 4, pp. 808 - 819
Abstract Purpose /Objective(s): To report clinical outcomes of head and neck reirradiation with proton therapy. Methods and Materials Between 2004–2014, 61... 
Radiology | Hematology, Oncology and Palliative Medicine | SALVAGE REIRRADIATION | CETUXIMAB | MANAGEMENT | PROGNOSTIC-FACTORS | UVEAL MELANOMA | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | PERINEURAL SPREAD | RADIOTHERAPY | RADIATION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | CHEMOTHERAPY | Neoplasm Recurrence, Local - radiotherapy | Follow-Up Studies | Skin Neoplasms - radiotherapy | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Salvage Therapy | Male | Neoplasms, Second Primary - mortality | Carcinoma, Squamous Cell - radiotherapy | Neoplasm Recurrence, Local - mortality | Neoplasms, Second Primary - radiotherapy | Neoplasm, Residual | Carcinoma, Squamous Cell - mortality | Karnofsky Performance Status | Time Factors | Aged, 80 and over | Adult | Female | Radiotherapy Dosage | Carcinoma, Adenoid Cystic - pathology | Re-Irradiation - adverse effects | Head and Neck Neoplasms - drug therapy | Kaplan-Meier Estimate | Treatment Outcome | Head and Neck Neoplasms - pathology | Head and Neck Neoplasms - radiotherapy | Carcinoma, Adenoid Cystic - mortality | Carcinoma, Squamous Cell - drug therapy | Proton Therapy | Aged | Carcinoma, Adenoid Cystic - radiotherapy | Head and Neck Neoplasms - mortality | Relative Biological Effectiveness | Yuan (China) | Medical colleges | Care and treatment | Health aspects | Radiation | Cancer | Index Medicus | HEAD | PATIENTS | NEOPLASMS | RADIOLOGY AND NUCLEAR MEDICINE | PROTON BEAMS | DEATH | RADIATION DOSES | NECK | GY RANGE 10-100
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases
by Hughes, Marybeth S and Hughes, Marybeth S and Zager, Jonathan and Zager, Jonathan and Faries, Mark and Faries, Mark and Alexander, H Richard and Alexander, H Richard and Royal, Richard E and Royal, Richard E and Wood, Bradford and Wood, Bradford and Choi, Junsung and Choi, Junsung and McCluskey, Kevin and McCluskey, Kevin and Whitman, Eric and Whitman, Eric and Agarwala, Sanjiv and Agarwala, Sanjiv and Siskin, Gary and Siskin, Gary and Nutting, Charles and Nutting, Charles and Toomey, Mary Ann and Toomey, Mary Ann and Webb, Carole and Webb, Carole and Beresnev, Tatiana and Beresnev, Tatiana and Pingpank, James F and Pingpank, James F
Annals of Surgical Oncology, ISSN 1068-9265, 4/2016, Volume 23, Issue 4, pp. 1309 - 1319
There is no consensus for the treatment of melanoma metastatic to the liver. Percutaneous hepatic perfusion with melphalan (PHP-Mel) is a method of delivering... 
Oncology | Medicine & Public Health | Surgical Oncology | Surgery | OCULAR MELANOMA | SURGERY | ISOLATED LIMB INFUSION | UVEAL MELANOMA | SURVIVAL BENEFIT | ONCOLOGY | SAFETY | SINGLE-INSTITUTION EXPERIENCE | REGIONAL THERAPY | IMMUNOEMBOLIZATION | MELPHALAN | ADVANCED EXTREMITY MELANOMA | Prognosis | Skin Neoplasms - drug therapy | Follow-Up Studies | Humans | Middle Aged | Hepatic Artery | Liver Neoplasms - drug therapy | Eye Neoplasms - secondary | Male | Survival Rate | Embolization, Therapeutic | Melanoma - pathology | Eye Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Perfusion | Melanoma - drug therapy | Skin Neoplasms - secondary | Adult | Female | Aged | Liver Neoplasms - secondary | Neoplasm Staging | Chemotherapy, Cancer, Regional Perfusion | Infusions, Intra-Arterial | Clinical trials | Liver cancer | Care and treatment | Metastasis | Comparative analysis | Patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors
by Naing, Aung and Papadopoulos, Kyriakos P and Autio, Karen A and Ott, Patrick A and Patel, Manish R and Wong, Deborah J and Falchook, Gerald S and Pant, Shubham and Whiteside, Melinda and Rasco, Drew R and Mumm, John B and Chan, Ivan H and Bendell, Johanna C and Bauer, Todd M and Colen, Rivka R and Hong, David S and Van Vlasselaer, Peter and Tannir, Nizar M and Oft, Martin and Infante, Jeffrey R
Journal of Clinical Oncology, ISSN 0732-183X, 10/2016, Volume 34, Issue 29, pp. 3562 - 3569
PurposeInterleukin-10 (IL-10) stimulates the expansion and cytotoxicity of tumor-infiltrating CD8+ T cells and inhibits inflammatory CD4+ T cells. Pegylation... 
MELANOMA | THERAPY | ONCOLOGY | INFLAMMATION | RECEPTOR | NIVOLUMAB | CANCER | CD8(+) T-CELLS | IL-10 | IPILIMUMAB | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - pharmacokinetics | Fatigue - chemically induced | Injections, Subcutaneous - adverse effects | Recombinant Proteins - adverse effects | Fever - chemically induced | Polyethylene Glycols - therapeutic use | Young Adult | Exanthema - chemically induced | Aged, 80 and over | Adult | Female | Carcinoma, Renal Cell - drug therapy | Interleukin-8 - blood | Cytokines - blood | Drug Eruptions - etiology | Interleukin-10 - pharmacokinetics | Anemia - chemically induced | Polyethylene Glycols - pharmacokinetics | Thrombocytopenia - chemically induced | Transforming Growth Factor beta - blood | Uveal Neoplasms - drug therapy | Neoplasms - drug therapy | Interleukin-4 - blood | Interleukin-10 - adverse effects | Recombinant Proteins - immunology | Melanoma - drug therapy | Aged | Interleukin-10 - therapeutic use | Kidney Neoplasms - drug therapy | Neoplasms - pathology | Interleukin-10 - immunology | Interferon-gamma - blood | Original Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma
by Alexander, Marliese and Mellor, James D and McArthur, Grant and Kee, Damien
Medical Journal of Australia, ISSN 0025-729X, 07/2014, Volume 201, Issue 1, pp. 49 - 53
Objectives: To evaluate the efficacy and tolerability of ipilimumab in an Australian clinical setting, and to assess the association of response with melanoma... 
Skin and connective tissue diseases | SURVIVAL | MEDICINE, GENERAL & INTERNAL | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Mucous Membrane | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Melanoma - genetics | Skin Neoplasms - mortality | Retrospective Studies | Skin Neoplasms - pathology | Uveal Neoplasms - genetics | Uveal Neoplasms - pathology | Drug Administration Schedule | Melanoma - pathology | Disease Progression | Uveal Neoplasms - drug therapy | Disease-Free Survival | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Uveal Neoplasms - mortality | Lymphocyte Count | Neoplasm Staging | Melanoma - mortality | Care and treatment | Dosage and administration | Analysis | Risk factors | Melanoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
by Carvajal, Richard D and Piperno-Neumann, Sophie and Kapiteijn, Ellen and Chapman, Paul B and Frank, Stephen and Joshua, Anthony M and Piulats, Josep M and Wolter, Pascal and Cocquyt, Veronique and Chmielowski, Bartosz and Evans, T.R. Jeffry and Gastaud, Lauris and Linette, Gerald and Berking, Carola and Schachter, Jacob and Rodrigues, Manuel J and Shoushtari, Alexander N and Clemett, Delyth and Ghiorghiu, Dana and Mariani, Gabriella and Spratt, Shirley and Lovick, Susan and Barker, Peter and Kilgour, Elaine and Lai, Zhongwu and Schwartz, Gary K and Nathan, Paul
Journal of Clinical Oncology, ISSN 0732-183X, 04/2018, Volume 36, Issue 12, pp. 1232 - 1239
PurposeUveal melanoma is the most common primary intraocular malignancy in adults with no effective systemic treatment option in the metastatic setting.... 
ONCOLOGY | GNAQ | GROWTH | MUTATIONS | AZD6244 ARRY-142886 | INHIBITOR | CANCER | Dacarbazine - administration & dosage | Dacarbazine - adverse effects | Uveal Neoplasms - pathology | Double-Blind Method | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Melanoma - pathology | Uveal Neoplasms - drug therapy | Neoplasm Metastasis | Benzimidazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Progression-Free Survival | Placebos | Adult | Female | Aged | Benzimidazoles - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Biology of advanced uveal melanoma and next steps for clinical therapeutics
by Luke, Jason J and Triozzi, Pierre L and McKenna, Kyle C and Van Meir, Erwin G and Gershenwald, Jeffrey E and Bastian, Boris C and Gutkind, J. Silvio and Bowcock, Anne M and Streicher, Howard Z and Patel, Poulam M and Sato, Takami and Sossman, Jeffery A and Sznol, Mario and Welch, Jack and Thurin, Magdalena and Selig, Sara and Flaherty, Keith T and Carvajal, Richard D
Pigment Cell & Melanoma Research, ISSN 1755-1471, 03/2015, Volume 28, Issue 2, pp. 135 - 147
Summary Uveal melanoma is the most common intraocular malignancy although it is a rare subset of all melanomas. Uveal melanoma has distinct biology relative to... 
MEK | Ocular | metastasis | GNAQ | GNA11 | Melanoma | cancer | Uveal | Metastasis | Cancer | Melanoma - etiology | Uveal Neoplasms - pathology | Signal Transduction | Humans | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Melanoma - pathology | Uveal Neoplasms - etiology | Uveal Neoplasms - drug therapy | Uveal Neoplasms - immunology | Melanoma - immunology | Melanoma - drug therapy | Biomedical Research | Neoplasm Staging | Therapeutics | Homeopathy | Materia medica and therapeutics | Medical research | Drug therapy | Gene expression
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma
by Zimmer, Lisa and Vaubel, Julia and Mohr, Peter and Hauschild, Axel and Utikal, Jochen and Simon, Jan and Garbe, Claus and Herbst, Rudolf and Enk, Alexander and Kämpgen, Eckhart and Livingstone, Elisabeth and Bluhm, Leonie and Rompel, Rainer and Griewank, Klaus G and Fluck, Michael and Schilling, Bastian and Schadendorf, Dirk
PLoS ONE, ISSN 1932-6203, 03/2015, Volume 10, Issue 3, pp. e0118564 - e0118564
Purpose Up to 50% of patients with uveal melanoma (UM) develop metastatic disease with limited treatment options. The immunomodulating agent ipilimumab has... 
SURVIVAL | TRIAL | CONJUNCTIVAL | DOSE-ESCALATION | SAFETY | IMMUNOTHERAPY | MULTIDISCIPLINARY SCIENCES | INTRAVENOUS FOTEMUSTINE | MUTATIONS | CANCER | TUMORS | History, Ancient | Uveal Neoplasms - pathology | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Antibodies, Monoclonal - therapeutic use | Treatment Outcome | Antineoplastic Agents - therapeutic use | Melanoma - secondary | Uveal Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Melanoma - drug therapy | Uveal Neoplasms - mortality | Aged, 80 and over | Adult | Female | Aged | Melanoma - mortality | Life expectancy | Dermatology | Toxicity | Medical treatment | Melanoma | Medical services | Clinical trials | Metastasis | Criteria | Dosage | Kinases | Disease control | Patients | Survival | Two phase | Metastases | Skin cancer | Lymphocytes | Medical prognosis | Pancytopenia | Mutation | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights